• Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Live Money Report
No Result
View All Result
Home Breaking News

Johnson & Johnson Stock Jumps on Reports It Plans to Split In Two

by
November 12, 2021
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter
Text size

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California

Mark Ralston/AFP via Getty Images


Johnson & Johnson

announced plans on Friday to split from its consumer health division, spelling the end of the last great pharmaceutical conglomerate.

Related Posts

A TikTok star paid off $17,000 in credit card debt by ‘cash stuffing’ — here’s how it could get your finances on track

Buy-the-dippers, take note: Wall Street’s most notorious bear sees a stock rally coming

‘We have a whole lot more to go down’: Suze Orman thinks we’re headed for a recession and warns that things may get a ‘little bit ugly.’ Here’s what she likes for safety

Billionaire Israel Englander Pulls the Trigger on These 2 “Strong Buy” Stocks

Johnson & Johnson (ticker: JNJ) shares were up on the news, which comes two months before a planned CEO transition, in which longtime Johnson & Johnson executive Joaquin Duato is slated to replace Alex Gorsky in the top post.

Johnson & Johnson said that the split will take 18 to 24 months. The consumer health division, which the company said is expected to generate $15 billion in revenue this year, will become a new publicly traded company, selling big-name brands home health brands like Band-Aid, Tylenol, and Listerine.

The pharmaceutical and medical devices divisions, which the company expects to generate revenue of $77 billion this year, will stay behind as a separate company, selling a range of treatments and devices, from balloons used in sinus procedures to bladder cancer therapies. Johnson & Johnson has chosen not to split those two business segments.

Today, with a market value of $432.5 billion, Johnson & Johnson is the largest pharmaceutical company in the world. Johnson & Johnson says that the stay-behind pharmaceutical and medical device business will remain the biggest pharmaceutical company in the world.

Johnson & Johnson stock was up 4.9% in premarket trading Friday, while

S&P 500
futures had advanced 0.2% and

Dow Jones Industrial Average
futures had risen 0.2%.

Johnson & Johnson has become something of an anachronism in recent years, as its competitors have shed their consumer health divisions one after another.


Pfizer

(PFE) handed its consumer health business to


GlaxoSmithKline

(GSK) in 2019; Glaxo is planning on spinning off the combined business soon.

The market has taken time to warm up to those deals.

Johnson & Johnson would be the third company with plans to break up that were revealed this week. General Electric (GE) said it will break itself up into three parts, while


Toshiba

has said it plans to split up as well.

Write to Ben Levisohn at ben.levisohn@barrons.com

Next Post

Stocks making the biggest moves premarket: Johnson & Johnson, Rivian, Lordstown and more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Breaking News

A TikTok star paid off $17,000 in credit card debt by ‘cash stuffing’ — here’s how it could get your finances on track

by
June 27, 2022
0

Read more

A TikTok star paid off $17,000 in credit card debt by ‘cash stuffing’ — here’s how it could get your finances on track

‘We have a whole lot more to go down’: Suze Orman thinks we’re headed for a recession and warns that things may get a ‘little bit ugly.’ Here’s what she likes for safety

Buy-the-dippers, take note: Wall Street’s most notorious bear sees a stock rally coming

Billionaire Israel Englander Pulls the Trigger on These 2 “Strong Buy” Stocks

What’s Holding Back Boeing’s 787 Dreamliner?

Trump-Tied SPAC Tumbles After Disclosing Grand Jury Subpoena

Load More

All rights reserved by www.livemoneyreport.com

  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.